Pasireotide—a novel somatostatin receptor ligand after 20 years of use
Sign Up to like & getrecommendations! Published in 2022 at "Reviews in Endocrine and Metabolic Disorders"
DOI: 10.1007/s11154-022-09710-3
Abstract: Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has been suggested… read more here.
Keywords: somatostatin receptor; pasireotide novel; receptor ligand; cushing disease ... See more keywords